Overview

A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)

Status:
RECRUITING
Trial end date:
2028-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effectiveness, safety, pharmacokinetics (PK) of SYHX2008 vs Octreotide Microspheres (Sandostatin LAR@) in patients with advanced, well-differentiated GEP-NET.
Phase:
PHASE2
Details
Lead Sponsor:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.